The impact of sex in primary glomerulonephritis

Nephrology Dialysis Transplantation

Volumn 23, Issue 7, 2008, Pages 2247-2253

  Cattran, Daniel C ^a,b   Reich, Heather N ^a   Beanlands, Heather J ^a   Miller, Judith A ^a   Scholey, James W ^a   Troyanov, Stéphan ^a  

^a TORONTO GENERAL HOSPITAL   (Canada)

^b NCSB 11 1256 ^*  (Canada)

Author keywords

Focal and segmental glomerulosclerosis; IgA nephropathy; Membranous nephropathy; Progression risk factors; Sex

Indexed keywords

ADOLESCENT; ADULT; ARTICLE; BLOOD PRESSURE; DISEASE COURSE; FEMALE; FOCAL GLOMERULOSCLEROSIS; HUMAN; IMMUNOGLOBULIN A NEPHROPATHY; KIDNEY FUNCTION; MAJOR CLINICAL STUDY; MALE; MEMBRANOUS GLOMERULONEPHRITIS; OUTCOME ASSESSMENT; PRIORITY JOURNAL; PROTEINURIA; RISK FACTOR; SEX DIFFERENCE; SURVIVAL;

ADULT; AGED; ANTIHYPERTENSIVE AGENTS; BLOOD PRESSURE; CREATININE; DISEASE PROGRESSION; FEMALE; FOLLOW-UP STUDIES; GLOMERULONEPHRITIS; GLOMERULONEPHRITIS, IGA; GLOMERULONEPHRITIS, MEMBRANOUS; GLOMERULOSCLEROSIS, FOCAL SEGMENTAL; HUMANS; IMMUNOSUPPRESSIVE AGENTS; KAPLAN-MEIERS ESTIMATE; MALE; MIDDLE AGED; PROGNOSIS; PROTEINURIA; RETROSPECTIVE STUDIES; RISK FACTORS; SEX FACTORS; TREATMENT OUTCOME;

EID: 46849108504     PISSN: 09310509     EISSN: 14602385     Source Type: Journal    
DOI: 10.1093/ndt/gfm919     Document Type: Article

References (60)

1. Neugarten J, Acharya A, Silbiger SR. Effect of gender on the progression of nondiabetic renal disease: a meta-analysis. J Am Soc Nephrol 2000; 11: 319-329
2. Coggins CH, Breyer Lewis J, Caggiula AW et al. Differences between women and men with chronic renal disease. Nephrol Dial Transplant 1998; 13: 1430-1437
3. Eriksen BO, Ingebretsen OC. The progression of chronic kidney disease: a 10-year population-based study of the effects of gender and age. Kidney Int 2006; 69: 375-382
4. Ruggenenti P, Perna A, Loriga G et al. Blood-pressure control for renoprotection in patients with non-diabetic chronic renal disease (REIN-2):multicentre, randomised controlled trial. Lancet 2005; 365: 939-946
5. Jungers P, Hannedouche T, Itakura Y et al. Progression rate to end-stage renal failure in non-diabetic kidney diseases: a multivariate analysis of determinant factors. Nephrol Dial Transplant 1995; 10: 1353-1360
6. D'Amico G. Influence of clinical and histological features on actuarial renal survival in adult patients with idiopathic IgA nephropathy, membranous nephropathy, andmembranoproliferative glomerulonephritis: survey of the recent literature. Am J Kidney Dis 1992; 20: 315-323
7. Jafar TH, Stark PC, Schmid CH et al. Progression of chronic kidney disease: the role of blood pressure control, proteinuria, and angiotensin-converting enzyme inhibition: a patient-level meta-analysis. Ann Intern Med 2003; 139: 244-252
8. Jafar TH, Schmid CH, Stark PC et al. The rate of progression of renal disease may not be slower in women compared with men: a patient-level meta-analysis. Nephrol Dial Transplant 2003; 18: 2047-2053
9. Peterson JC, Adler S, Burkart JM et al. Blood pressure control, proteinuria and the progression of renal disease. The Modification of Diet in Renal Disease Study. Ann Intern Med 1995; 123: 754-762
10. Regional Program for the Study of Glomerulonephritis. Central Committee of the Toronto Glomerulonephritis Registry. Can Med Assoc J 1981; 124: 158-161
11. Cockcroft DW, Gault MH. Prediction of creatinine clearance from serum creatinine. Nephron 1976; 16: 31-41
12. Verbraecken J, Van de Heyning P, De Backer W et al. Body surface area in normal-weight, overweight, and obese adults. A comparison study. Metabolism 2006; 55: 515-524
13. Troyanov S, Wall CA, Miller JA et al. Idiopathic membranous nephropathy: Definition and relevance of a partial remission. Kidney Int 2004; 66: 1199-1205
14. Troyanov S, Wall CA, Miller JA et al. Focal and segmental glomerulosclerosis: definition and relevance of a partial remission. J Am Soc Nephrol 2005; 16: 1061-1068
15. Cattran DC, Appel GB, Hebert LA et al. (North America Nephrotic Syndrome Study Group). A randomized trial of cyclosporine in patients with steroid-resistant focal segmental glomerulosclerosis. Kidney Int 1999; 56: 2220-2226
16. Ponticelli C, Passerini P, Altieri P et al. Remissions and relapses in idiopathic membranous nephropathy. Nephrol Dial Transplant 1992; 1(Suppl): 85-90
17. Katz MH. Multivariable analysis: a primer for readers of medical research. Ann Intern Med 2003; 138: 644-650
18. Li PK, Leung CB, Chow KM et al. Hong Kong study using valsartan in IgA nephropathy (HKVIN): a double-blind, randomized, placebo-controlled study. Am J Kidney Dis 2006; 47: 751-760
19. Bos H, Henning RH, De Jong PE et al. Do severe systemic sequelae of proteinuria modulate the antiproteinuric response to chronic ACE inhibition? Nephrol Dial Transplant 2002; 17: 793-797
20. Jude EB, Anderson SG, Cruickshank JK et al. Natural history and prognostic factors of diabetic nephropathy in type 2 diabetes. QJM 2002; 95: 371-377
21. K/DOQI Clinical Practice Guidelines for Chroic Kidney Disease. Evaluation, classification and stratification: Part 5. Evaluation of laboratory measurements for clinical assessment of kidney disease. Am J Kidney Dis 2002; 1(Suppl): s76-s111
22. Reckelhoff JF. Gender differences in the regulation of blood pressure. Hypertension 2001; 37: 1199-1208
23. Cameron JS, Healy MJ, Adu D (The MRC Glomerulonephritis Working Party). The Medical Research Council trial of short-term high-dose alternate day prednisolone in idiopathic membranous nephropathy with nephrotic syndrome in adults. Q J Med 1990; 74: 133-156
24. Zucchelli P, Ponticelli C, Cagnoli L et al. Long-term outcome of idiopathic membranous nephropathy with nephrotic syndrome. Nephrol Dial Transplant 1987; 2: 73-78
25. Murphy BF, Fairley KF, Kincaid-Smith PS. Idiopathic membranous glomerulonephritis: long-term follow-up in 139 cases. Clin Nephrol 1988; 30: 175-181
26. Donadio JV, Jr., Torres VE, Velosa JA et al. Idiopathic membranous nephropathy: the natural history of untreated patients. Kidney Int 1988; 33: 708-715
27. Schieppati A, Mosconi L, Perna A et al. Prognosis of untreated patients with idiopathic membranous nephropathy. N Engl J Med 1993; 329: 85-89
28. Hopper J, Jr., Trew PA, Biava CG. Membranous nephropathy: its relative benignity in women. Nephron 1981; 29: 18-24
29. Toth T, Takebayashi S. Factors contributing to the outcome in 100 adult patients with idiopathic membranous glomerulonephritis. Int Urol Nephrol 1994; 26: 93-106
30. A controlled study of short-term prednisone treatment in adults with membranous nephropathy. Collaborative study of the adult idiopathic nephrotic syndrome. N Engl J Med 1979; 301: 1301-1306
31. Honkanen E, Tornroth T, Gronhagen-Riska C et al. Long-term survival in idiopathic membranous glomerulonephritis: can the course be clinically predicted? Clin Nephrol 1994; 41: 127-134
32. Wehrmann M, Bohle A, Bogenschutz O et al. Long-term prognosis of chronic idiopathic membranous glomerulonephritis. An analysis of 334 cases with particular regard to tubulo-interstitial changes. Clin Nephrol 1989; 31: 67-76
33. Wehrmann M, Bohle A, Held H et al. Long-term prognosis of focal sclerosing glomerulonephritis. An analysis of 250 cases with particular regard to tubulointerstitial changes. Clin Nephrol 1990; 33: 115-122
34. Chitalia VC, Wells JE, Robson RA et al. Predicting renal survival in primary focal glomerulosclerosis from the time of presentation. Kidney Int 1999; 56: 2236-2242
35. Schwartz MM, Evans J, Bain R et al. Focal segmental glomerulosclerosis: prognostic implications of the cellular lesion. J Am Soc Nephrol 1999; 10: 1900-1907
36. Banfi G, Moriggi M, Sabadini E et al. The impact of prolonged immunosuppression on the outcome of idiopathic focal-segmental glomerulosclerosis with nephrotic syndrome in adults. A collaborative retrospective study. Clin Nephrol 1991; 36: 53-59
37. Meyrier A, Noel LH, Auriche P et al. (Collaborative Group of the Societe de Nephrologie). Long-term renal tolerance of cyclosporin A treatment in adult idiopathic nephrotic syndrome. Kidney Int 1994; 45: 1446-1456
38. Rydel JJ, Korbet SM, Borok RZ et al. Focal segmental glomerular sclerosis in adults: presentation, course, and response to treatment. Am J Kidney Dis 1995; 25: 534-542
39. Valeri A, Barisoni L, Appel GB et al. Idiopathic collapsing focal segmental glomerulosclerosis: a clinicopathologic study. Kidney Int 1996; 50: 1734-1746
40. Velosa JA, Donadio JV, Jr, Holley KE. Focal sclerosing glomerulonephropathy: a clinicopathologic study. Mayo Clin Proc 1975; 50: 121-133
41. Haas M. Histologic subclassification of IgA nephropathy: a clinico-pathologic study of 244 cases. Am J Kidney Dis 1997; 29: 829-842
42. Alamartine E, Sabatier JC, Guerin C et al. Prognostic factors in mesangial IgA glomerulonephritis: an extensive study with univariate and multivariate analyses. Am J Kidney Dis 1991; 18: 12-19
43. Radford MG, Jr, Donadio JV, Jr, Bergstralh EJ et al. Predicting renal outcome in IgA nephropathy. J Am Soc Nephrol 1997; 8: 199-207
44. Koyama A, Igarashi M, Kobayashi M (Research Group on Progressive Renal Diseases). Natural history and risk factors for immunoglobulin A nephropathy in Japan. Am J Kidney Dis 1997; 29: 526-532
45. D'Amico G, Minetti L, Ponticelli C et al. Prognostic indicators in idiopathic IgA mesangial nephropathy. Q J Med 1986; 59: 363-378
46. Bogenschutz O, Bohle A, Batz C et al. IgA nephritis: on the importance of morphological and clinical parameters in the long-term prognosis of 239 patients. Am J Nephrol 1990; 10: 137-147
47. Johnston PA, Brown JS, Braumholtz DA et al. Clinico-pathological correlations and long-term follow-up of 253 United Kingdom patients with IgA nephropathy. A report from the MRC Glomerulonephritis Registry. Q J Med 1992; 84: 619-627
48. Katafuchi R, Oh Y, Hori K et al. An important role of glomerular segmental lesions on progression of IgA nephropathy: a multivariate analysis. Clin Nephrol 1994; 41: 191-198
49. Packham DK, Yan HD, Hewitson TD et al. The significance of focal and segmental hyalinosis and sclerosis (FSHS) and nephrotic range proteinuria in IgA nephropathy. Clin Nephrol 1996; 46: 225-229
50. Rambausek M, Rauterberg EW, Waldherr R et al. Evolution of IgA glomerulonephritis: relation to morphology, immunogenetics and BP. Semin Nephrol 1987; 7: 370-373
51. Nicholls KM, Fairley KF, Dowling JP et al. The clinical course of mesangial IgA associated nephropathy in adults. Q J Med 1984; 53: 227-250
52. Droz D, Kramar A, Nawar T et al. Primary IgA nephropathy: prognostic factors. Contrib Nephrol 1984; 40: 202-207
53. Velo M, Lozano L, Egido J et al.Natural history of IgA nephropathy in patients followed-up for more than ten years in Spain. Semin Nephrol 1987; 7: 346-350
54. Donadio JV, Bergstralh EJ, Offord KP et al. (Mayo Nephrology Collaborative Group). Clinical and histopathologic associations with impaired renal function in IgA nephropathy. Clin Nephrol 1994; 41: 65-71
55. Frimat L, Briancon S, Hestin D et al. (L'Association des Nephrologues de l'Est). IgA nephropathy: prognostic classification of end-stage renal failure. Nephrol Dial Transplant 1997; 12: 2569-2575
56. Rekola S, Bergstrand A, Bucht H. Deterioration of GFR in IgA nephropathy as measured by 51 Cr-EDTA clearance. Kidney Int 1991; 40: 1050-1054
57. Simon P, Ramee MP, Autuly V et al. Epidemiology of primary glomerular diseases in a French region. Variations according to period and age. Kidney Int 1994; 46: 1192-1198
58. Silbiger SR, Neugarten J. The impact of gender on the progression of chronic renal disease. Am J Kidney Dis 1995; 25: 515-533
59. Reckelhoff JF, Hennington BS, Moore AG et al. Gender differences in the renal nitric oxide (NO) system: dissociation between expression of endothelial NO synthase and renal hemodynamic response to NO synthase inhibition. Am J Hypertens 1998; 11: 97-104
60. Miller JA, Anacta LA, Cattran DC. Impact of gender on the renal response to angiotensin II. Kidney Int 1999; 55: 278-285